Metrics raised 1
- 5,000-bed capacity target timeline accelerated to ~2.5 years (from ~3 years prior)
Event Participants
Executives (6)
Amit Kumar Singh, Ashutosh Kumar Jha, Nitin Gupta, Pankaj Prabhakar, Sonu Goyal, Yatharth Tyagi
Analysts (14)
Akshat Mehta (Seven Rivers Holding), Akshay Shinde (Centrum Broking), Anuj Kashyap (A3 Capital), Ashish T (UTI), Bhagwat (Prosperity Wealth Management), Disha Parakh (Sunidhi Securities & Finance), Nishita (Sapphire Capital), Prerana Amanna (Equity Research Program), Prinita (RediStock Capital), Satyam Kumar (AAA Holdings), Surbhi Gupta (Trinetra Asset Managers), Vedant Kabra (AVN Capital), Vicky Waghwani (Guardian Capital), Virat Pansuriya (Skyridge Wealth Management)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹3,200 million (₹320 crore) | +51% YoY, +15% QoQ; highest ever quarterly revenue, driven by newer hospitals contributing 27% to revenue mix |
| Existing Hospitals Revenue | ₹2,862 million | +22% YoY from Noida cluster and Jhansi-Orchha; occupancy ~75% for existing base |
| Newer Hospitals Revenue | ₹1,067 million | 27% of group revenue; includes Greater Faridabad, New Delhi, Faridabad Sector 20 and Agra |
| EBITDA | ₹917 million | +39% YoY; highest ever quarterly EBITDA, operating leverage kicking in |
| EBITDA Margin | 23.3% consolidated; 28.1% adjusted | Adjusted excludes New Delhi & Faridabad Sector 20; blended margin expected to improve as new hospitals scale |
| PAT | ₹454 million | Highest ever quarterly PAT; cash profit (PAT + depreciation) up +32% YoY |
| ARPOB | ₹34,758 | +7% YoY; all-time high; Noida Extension and New Delhi crossed ₹50,000 for first time |
| Occupancy | ~75% existing hospitals; ~68% overall | Noida and Jhansi-Orchha at 90%+; Greater Noida 74%, Noida Extension 56%, Agra 89% |
| Bed Capacity | 2,555 beds (1,820 census beds) | 3,200+ announced capacity; 5,000-bed target expected in ~2.5–3 years |
| Oncology Contribution | ~10% of group revenue | Currently one Linac at Noida Extension; adding second at Faridabad Sector 20, soon followed by New Delhi |
Geographic & Segment Commentary
Noida Cluster (Noida, Noida Extension, Greater Noida): Existing three hospitals collectively grew 22% YoY with ~75% occupancy. Noida Extension crossed ₹50,000 ARPOB for the first time; Greater Noida at ~₹43,000. Brownfield expansion of ~450 beds planned across Noida Extension and Greater Noida, operational in 15–18 months.
Delhi NCR New Hospitals (New Delhi Model Town, Faridabad Sector 20): Faridabad Sector 20 achieved EBITDA break-even in a record nine months (vs 12–14 month target) with monthly run-rate of ₹12–13 crore and ARPOB ~₹40,000, heading to ₹45–50,000. New Delhi Model Town at ~₹50,000 ARPOB with ₹8 crore monthly run-rate, 29% occupancy on 150 census beds; 90%+ cash/private payer mix at both facilities; break-even guided for Q3–Q4 FY27.
Agra & Jhansi-Orchha: Agra delivered ₹9–10 crore monthly revenue run-rate with 20%+ EBITDA margin in its first full quarter of integration; running on only 110 of 250 census beds at 89% occupancy with plans to expand census capacity. Jhansi-Orchha at 91% occupancy with ₹13,000 ARPOB.
Gurugram (Upcoming): 250-bed premium facility under construction as per schedule, expected operational by Q1 FY28 with potential ARPOB of ₹50,000+; positioned to strengthen premium NCR network.
Company-Specific & Strategic Commentary
Acquisition & Integration Playbook: Sector 20 broke even in 9 months (vs 12–14 month plan) with <10% government business; Agra hit 20%+ EBITDA in first full quarter; management demonstrated ability to identify, integrate and turn around assets rapidly within existing clusters.
Premium Payer Mix Strategy: New hospitals running at 90%+ cash/private insurance patients; management deliberately restricting government business at new facilities; group government payer mix ~40% (impacted by 1–2% CGHS price revision, volumes actually declining).
Oncology Expansion: Oncology contributing ~10% of group revenue with single Linac; adding Linac at Faridabad Sector 20 and New Delhi facility to meaningfully strengthen oncology share in coming years.
International Patient Outreach: Opened Yatharth Information Center in Uzbekistan; planning five OPD/information centers across CIS and African countries; senior marketing personnel deployed in African region to build medical tourism flows.
Capital Returns & Talent Initiatives: Board approved maiden interim dividend of 5% of face value; launched ESOP Scheme 2026 with first grant to attract/retain talent; identifying ESG priorities across hospital network.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | Surpass FY26's 37% YoY | Driven by new hospital ramp-up, high occupancy in existing assets, and full-year Agra contribution |
| FY27 EBITDA Margin | ~24% (full year) | Includes new hospital drags; adjusts to ~28%+ at mature assets |
| FY27 RPOP Growth | 8–10% YoY | Mix improvement from premium NCR hospitals; sustainable going forward |
| Model Town Break-even | Q3–Q4 FY27 | On track for 15–17 month timeline; Sector 20 already break-even |
| Bed Capacity | 3,200+ announced; 5,000 target in ~2.5–3 years | Gurugram live Q1 FY28; brownfield additions in 15–18 months; possibly earlier than announced 3-year target |
| Capex per Bed | ₹75–80 lakhs for next ~1,800 beds | Includes land, construction, equipment; Gurugram runs ~₹1 crore/bed |
| New Hospital EBITDA Margins | 26–27% within ~2 years of break-even | Agra already at 20–23%; Sector 20 in 15 months |
| FY28–FY29 Revenue Growth | "Sustainable" at similar trajectory | Management expects continued momentum with one hospital addition per year |
Risks & Constraints
| Risk | Context |
|---|---|
| Government Price Regulation | NITI Aayog panel reportedly recommended capping hospital room charges at 3-star hotel level; management downplayed citing historical support for private hospitals (CGHS rate revision, stent/implants caps being non-material), but regulatory action could pressure tariffs |
| Interest Cost & PAT Margin Pressure | Debt increased from ₹210 crore (Mar FY26) to ~₹300 crore due to acquisition funding; interest cost at ₹6.6 crore/quarter; management expects no fresh loans in FY27 so pressure should normalize, but PAT margin has been impacted |
| New Hospital Ramp-Up Risk | Model Town at 29% occupancy; Faridabad Sector 20 only at 4–5% EBITDA margin post break-even; break-even timelines (Q3–Q4 FY27) subject to execution; Gurugram launch in Q1 FY28 adds new drag |
| margin Dilution from New Additions | Gurugram and future acquisitions will continue to dilute consolidated EBITDA; management guides ~24% for FY27 but near-term upside limited until new assets mature |
Q&A Highlights
5,000-Bed Target & Expansion Geography
- Question: Is the 5,000-bed target 3 years or 5 years? Will you expand beyond the Haryana/UP clusters? (Surbhi Gupta)
- Answer: Announced capacity already over 3,200 beds; 5,000-bed target likely achieved earlier than 3 years (est. ~2.5 years). Strategy remains within north India clusters - Delhi NCR and metro cities in UP; evaluating capital cities in Rajasthan and Haryana. New hospitals expected at ₹50,000+ RPOP. (Yatharth Tyagi)
New Hospital Occupancy & Break-even
- Question: Occupancy at Delhi and Faridabad seems stagnant - when will it improve? (Akshat Mehta)
- Answer: Occupancy numbers misleading because census beds increased (Delhi from 100 to 150, Faridabad from 100 to 200 this quarter); IPD volumes and revenue growing QoQ. Faridabad Sector 20 overperformed - break-even in 9 months vs 12–14 month plan; Model Town on track for 15–17 month break-even in Q3–Q4 FY27. (Yatharth Tyagi, Nitin Gupta)
Agra Hospital Expansion
- Question: At 89% occupancy, will you operationalize more census beds? (Akshat Mehta)
- Answer: Running on 110 of 250 census beds; plans underway to increase census bed capacity in coming quarters to capture full occupancy leverage. (Nitin Gupta, Yatharth Tyagi)
FY27 Financial Guidance
- Question: What growth should we expect for FY27? (Nishita)
- Answer: On track to surpass last year's 37% revenue growth; EBITDA margin ~24% for full year; RPOP growth 9–10%; PAT parameters similarly guided. Company should achieve or surpass guided targets. (Yatharth Tyagi)
EBITDA Margin Trajectory & Operating Leverage
- Question: When do new assets fall in line and when do we reach 26–27% margins? (Ashish T, Vedant Kabra)
- Answer: Sector 20 currently at 4–5% EBITDA margin; will take ~15 months to reach 15–20%. Model Town break-even in Q3–Q4 FY27. Incremental EBITDA on new patient volumes at mature occupancy ~22–23%. Group level target stays ~24% due to Gurugram and future acquisitions; new hospitals should reach 26–27% within ~2 years. (Yatharth Tyagi, Nitin Gupta)
Government Room Charge Regulation
- Question: Concern about NITI Aayog recommendation capping room charges to 3-star hotel level? (Ashish T)
- Answer: Not worried - multiple such recommendations in past (stent caps, implant caps) were managed; government has historically supported private hospitals (CGHS rates revised recently for first time in years). Even if implemented, hospitals would optimize costs. (Yatharth Tyagi, Unidentified Speaker)
Payer Mix & International Patient Strategy
- Question: How are you improving payer mix and international patient flows? (Surbhi Gupta, Satyam Kumar)
- Answer: Government payers ~40% of group revenue (up 1–2% from CGHS price revision, but volumes declining); new hospitals at 90%+ cash/private mix. International outreach: info centers opened in Uzbekistan, 5 more planned in CIS/Africa; senior marketing person posted to Africa; expect payer mix and ARPOB uplift. (Yatharth Tyagi, Unidentified Speaker)
PAT Margin Pressure & Capex
- Question: PAT margins severely impacted - any one-offs or should this persist? (Satyam Kumar)
- Answer: High capex in Q1 (Gurugram construction, oncology machines for Faridabad and Model Town) drove up debt and interest; depreciation also elevated. No fresh large capex planned in coming quarters, so interest and depreciation pressure should decrease from here. (Yatharth Tyagi, Nitin Gupta)
Capex per Bed & Funding
- Question: Capex per bed went from ₹30.7 lakh to ₹61.4 lakh - why, and what's forward outlook? (Virat Pansuriya)
- Answer: Historical costs lower due to cheaper land purchased years ago and phased equipment investment; today's real estate and equipment costs much higher - Gurugram ~₹1 crore/bed. Forward capex per bed ₹75–80 lakhs for remaining ~1,800 beds. Funding via internal accruals (₹210 crore → ₹300 crore debt, remainder paid from accruals); comfortable taking debt up to ~2x LTM EBITDA. (Yatharth Tyagi, Nitin Gupta)
Doctor Attrition & Retention
- Question: What is doctor attrition and how does ESOP fit into retention strategy? (Anuj Kashyap)
- Answer: Overall attrition ~7%, senior doctors ~3–4%; DNB programs help retain junior doctors for 3-year terms. ESOP Scheme 2026 is now a necessity for attracting top talent; doctor-friendly governance with department autonomy is key differentiator in NCR market. (Nitin Gupta, Yatharth Tyagi)
ARPOB Evolution & Medium-Term Targets
- Question: How will RPOP evolve with international patients and oncology additions over next 2–3 years? (Akshay Shinde)
- Answer: RPOP growth of 8–10% YoY sustainable; new hospitals should achieve 26–27% EBITDA margins within 2 years (Agra already at 20–23%); occupancy ramp-up offers long runway. Revenue growth for FY28–29 expected to remain elevated. (Yatharth Tyagi)
Key Takeaway
Yatharth Hospital delivered its strongest quarter ever in Q1 FY27, with revenue of ₹320 crore (+51% YoY), EBITDA of ₹91.7 crore (+39% YoY) and PAT of ₹45.4 crore, driven by newer hospitals contributing 27% of revenue. The acquisition playbook validated with Faridabad Sector 20 breaking even in nine months versus a 12–14-month plan, Agra delivering 20%+ EBITDA in its first full quarter, and premium NCR facilities achieving ₹50,000 ARPOB with 90%+ private/cash payer mix. Management guided to FY27 revenue growth above last year's 37%, EBITDA margin of ~24%, and 8–10% RPOP growth. The 5,000-bed target is expected closer to 2.5 years, with Gurugram (250 beds) launching Q1 FY28 and brownfield Noida expansions (450 beds) in 15–18 months. Key watch points include Model Town break-even in Q3–Q4 FY27, normalization of interest/depreciation post heavy capex, occupancy ramp at newer assets, and potential government room-charge regulation. Management remains confident of sustaining momentum through continued asset additions and cost discipline.